FDA WARNING_LETTER - White Eagle Native Herbs - May 12, 2020
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
On May 14, 2020, the FDA and FTC issued a Warning Letter to White Eagle Native Herbs regarding unapproved and misbranded products related to COVID-19. The agencies reviewed the company's website, whiteeaglenativeherbs.net, on May 7 and May 12, 2020, respectively.
The FDA observed that the website offered herbal products intended to mitigate, prevent, treat, diagnose, or cure COVID-19. These products are deemed unapproved new drugs, violating section 505(a) of the FD&C Act (21 U.S.C. § 355(a)), and misbranded drugs under section 502 of the FD&C Act (21 U.S.C. § 352). The introduction of these products into interstate commerce is prohibited by sections 301(a) and (d) of the FD&C Act (21 U.S.C. § 331(a) and (d)).
The letter cites the public health emergency and national emergency declarations for COVID-19 as context for urgent FDA action. The company is required to immediately cease selling these unapproved and unauthorized products for COVID-19 related uses. Examples of claims establishing intended use and misleadingly representing products as safe/effective for COVID-19 treatment/prevention were noted.
The
ID · d1a563b1-5ef5-43d2-9a00-f6f8de80e669
Full citation text and observation details available on the Dashboard.